Impact of Hodgkin or non-Hodgkin lymphoma and their treatments on sperm aneuploidy: a prospective study by the French CECOS network Guillaume Martinez, Ph.D., Marie Walschaerts, Ph.D., Marine Le Mitouard, B.Sc., Remi Borye, M.Sc., Claire Thomas, M.D., Jacques Auger, M.D., Ph.D., Isabelle Berthaut, Ph.D., Florence Brugnon, M.D., Ph.D., Myriam Daudin, M.D., Nathalie Moinard, D.Pharm., Célia Ravel, M.D., Ph.D., Jacqueline Saias, M.D., Ethel Szerman, Ph.D., Nathalie Rives, M.D., Ph.D., Sylviane Hennebicq, M.D., Ph.D., Louis Bujan, M.D., Ph.D. Fertility and Sterility Volume 107, Issue 2, Pages 341-350.e5 (February 2017) DOI: 10.1016/j.fertnstert.2016.10.001 Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions
Figure 1 Mean percentages of chromosomal abnormalities and SEMs before and during posttreatment follow-up: total chromosomal abnormalities, disomy, 24X/Y,+18, and diploidy. *P<.05, pre- and posttreatment difference. #P<.05, difference between controls and lymphoma patients. Means and SDs are given at each time point. Fertility and Sterility 2017 107, 341-350.e5DOI: (10.1016/j.fertnstert.2016.10.001) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions
Supplemental Figure 1 Design of the prospective study. Fertility and Sterility 2017 107, 341-350.e5DOI: (10.1016/j.fertnstert.2016.10.001) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions
Supplemental Figure 2 Mean percentages of total chromosomal abnormalities and SEMs before and during posttreatment follow-up according to type of treatment (ABVD ± radiotherapy, or CHOP/MOPP-ABV) and in the control group. *P<.05, pre- and posttreatment difference. #P<.05, difference between controls and lymphoma patients. Fertility and Sterility 2017 107, 341-350.e5DOI: (10.1016/j.fertnstert.2016.10.001) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions